{"database": "lobbying", "table": "lobbying_activities", "rows": [[2998412, "7982292d-9389-4a55-9d2a-77ba060d07e7", "Q2", "CARDINAL POINT PARTNERS", 308992, "TONIX PHARMACEUTICALS, INC.", 2023, "second_quarter", "DEF", "Biodefense medical countermeasures research and development in the National Defense Authorization Act for FY2024 (no bill numbers).", "HOUSE OF REPRESENTATIVES,SENATE", 30000, null, 0, 0, "2023-07-03T14:02:01-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["2998412"], "units": {}, "query_ms": 0.3608929691836238, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}